AVEO Pharmaceuticals Inc. (AVEO)

0.72
NASDAQ : Health Technology
Prev Close 0.72
Day Low/High 0.70 / 0.73
52 Wk Low/High 0.49 / 3.59
Avg Volume 6.60M
Exchange NASDAQ
Shares Outstanding 160.74M
Market Cap 115.81M
P/E Ratio N/A
Div & Yield N.A. (N.A)
Why Aveo's Tivozanib Should Win FDA Approval

Why Aveo's Tivozanib Should Win FDA Approval

Aveo's Tivozanib kidney cancer drug will get the nod from regulators.

AVEO Pharmaceuticals Enters Oversold Territory (AVEO)

AVEO Pharmaceuticals Enters Oversold Territory (AVEO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks

Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks

Ahead of Thursday's FDA panel, the agency asks if Aveo should conduct a second clinical trial.

Prepping for Aveo, Delcath FDA Panels

Prepping for Aveo, Delcath FDA Panels

It's a big week for Aveo and Delcath, starting Tuesday with FDA reviews of their respective cancer products.

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer is keeping up with earnings all week and the unemployment numbers Friday.

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

A close examination of survival data from Aveo's phase III study raises concerns.

Biotech's Next Big Thing: Aveo

Biotech's Next Big Thing: Aveo

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks

A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.

Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

AVEO Oncology To Present At The Barclays Global Healthcare Conference

AVEO Oncology To Present At The Barclays Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

AVEO And Astellas Announce FDA Advisory Committee To Review Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO And Astellas Announce FDA Advisory Committee To Review Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc.

AVEO Oncology To Present At The 2013 RBC Capital Markets’ Healthcare Conference

AVEO Oncology To Present At The 2013 RBC Capital Markets’ Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

New survival data from the phase III study of Aveo's tivozanib were released Tuesday night.

AVEO And Astellas Report Final Overall Survival Results From TIVO-1

AVEO And Astellas Report Final Overall Survival Results From TIVO-1

AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 ( TIvozanib Versus s Orafenib in 1 st line...

Aveo Pharma Readies Survival Update For Kidney Cancer Drug

Aveo Pharma Readies Survival Update For Kidney Cancer Drug

New survival data on Aveo's tivozanib to be presented at a medical meeting next week.

AVEO Oncology Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Conference Call

AVEO Oncology Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Conference Call

AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013.

AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be ...

AVEO Announces Closing Of Public Offering

AVEO Announces Closing Of Public Offering

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock.

AVEO Announces Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Announces Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of...

AVEO Prices Public Offering Of Common Stock

AVEO Prices Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.

AVEO Announces Proposed Public Offering Of Common Stock

AVEO Announces Proposed Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock.

J.P. Morgan Healthcare Confab Live Blog Day Two

J.P. Morgan Healthcare Confab Live Blog Day Two

Live coverage of biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

Shake the Bushes

I'm looking for the hot themes or groups of 2013.

13 Biotech Stock Predictions for 2013

13 Biotech Stock Predictions for 2013

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.

AVEO Oncology To Present At The 31st Annual J.P. Morgan Healthcare Conference

AVEO Oncology To Present At The 31st Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31 st Annual J.

Put These Flyers Under Your Tree

These stocks may be speculative, but they sport solid sales-growth estimates -- and insiders are buying.  

TheStreet Quant Rating: D- (Sell)